Congenital Heart Disease Treatment Market: ACE Inhibitors Segment to Dominate Global Market

Congenital heart disease is a structural heart issue existing at the time of birth. It is one of the most common types of birth defects across the globe.

Congenital Heart Disease Treatment Market: Introduction

  • Congenital heart disease is a structural heart issue existing at the time of birth. It is one of the most common types of birth defects across the globe.
  • In congenital heart disease, structure of the heart is developed abnormally. This includes defective heart valves, weak heart valves, and poor thickness of the heart arteries and veins. The abnormal heart structure leads to several complications such as low blood flow through the heart, blood flow in a wrong direction, and blockage of blood flow.
  • Congenital heart disease can be diagnosed through physical examination and special heart tests. It can also be diagnosed during pregnancy.
  • Common symptoms of congenital heart disease include poor blood circulation, rapid breathing, cyanosis, and fatigue. Most patients with the congenital heart disease show very less or no symptoms at early stages of the disease.
  • The treatment of congenital heart disease includes use of drugs, catheter procedure, surgery, and heart transplant

Request Brochure of Congenital Heart Disease Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75169

Global Congenital Heart Disease Treatment Market: Key Drivers

  • The global congenital heart disease treatment market is primarily driven by rise in the rate of incidence of congenital heart disease and launch of new products across the globe. The Centers for Disease Control and Prevention (CDC) estimates that one million children and one million adults in the U.S. are living with congenital heart disease currently.
  • Also, advancements in early diagnosis of congenital heart disease and availability of new therapeutic drugs are likely to fuel the global congenital heart disease treatment market during the forecast period
  • The family history of congenital heart disease and presence of underlying medical conditions, such as rubella, Type-1 diabetes, and Type-2 diabetes, during pregnancy increase chances of developing congenital heart disease in babies

Request for Analysis of COVID-19 Impact on Congenital Heart Disease Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75169

ACE Inhibitors Segment to Dominate Global Market

  • Based on drug class, the global congenital heart disease treatment market can be divided into angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers, antiarrhythmics, anticoagulants, antiplatelets, beta blockers, bosentan, digoxin, diuretics, sildenafil, and warfarin. The ACE inhibitors segment is anticipated to dominate the global market during the forecast period.
  • ACE inhibitors are most commonly used for the treatment of high blood pressure and congestive heart failure. The most commonly prescribed ACE inhibitors are captopril, enalapril, lisinopril, ramipril, and trandolapril.

Purchase the Congenital Heart Disease Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=75169&ltype=S

Retail Pharmacy Segment to Dominate Global Market

  • In terms of distribution channel, the global congenital heart disease treatment market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is projected to dominate the global congenital heart disease treatment market during the forecast period.
  • Easy availability of drugs for the treatment of congenital heart disease at retail pharmacy stores, presence of a large number of retail pharmacy stores across the globe, and rapidly growing number of retail pharmacy chains are factors responsible for the leading share of the retail pharmacy segment

Congenital Heart Disease Treatment Market in Asia Pacific to Expand Rapidly

  • In terms of region, the global congenital heart disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period. However, the region is anticipated to lose market share by 2027.
  • High prevalence of congenital heart disease among people in the U.S., technological advancements in early diagnosis of the disease, and increase in awareness about congenital heart disease in the region are projected to drive the market in North America from 2019 to 2027
  • The congenital heart disease treatment market in Asia Pacific is projected to expand at a high CAGR during the forecast period, owing to rapid increase in the number of patients with congenital heart disease, high prevalence of diabetes in densely populated countries such as India, China, and South Korea, and rapidly improving health care infrastructure in the region

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=75169

Key Players Operating in Global Market

The global congenital heart disease treatment market is highly fragmented, with a large number of global players accounting for a major share of the market in respective regions. Key players operating in the global congenital heart disease treatment market are:

  • Novartis AG
  • Bayer AG
  • Merck & Co. Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Abbott
  • Orion Corporation
  • Cardiorentis Ag

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/